Could Vericel Corporation (NASDAQ:VCEL) Change Direction After More Shorts?

June 13, 2018 - By Michael Pereira

Vericel Corporation (NASDAQ:VCEL) Logo

The stock of Vericel Corporation (NASDAQ:VCEL) registered an increase of 15.54% in short interest. VCEL’s total short interest was 1.51M shares in June as published by FINRA. Its up 15.54% from 1.30 million shares, reported previously. With 738,700 shares average volume, it will take short sellers 2 days to cover their VCEL’s short positions. The short interest to Vericel Corporation’s float is 5.3%.

The stock decreased 2.26% or $0.3 during the last trading session, reaching $12.95. About 646,258 shares traded. Vericel Corporation (NASDAQ:VCEL) has risen 389.29% since June 13, 2017 and is uptrending. It has outperformed by 376.72% the S&P500.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $549.49 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 4 analysts covering Vericel Corp (NASDAQ:VCEL), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vericel Corp had 6 analyst reports since January 2, 2018 according to SRatingsIntel. The company was maintained on Tuesday, January 2 by Piper Jaffray. The firm has “Buy” rating given on Wednesday, March 28 by BTIG Research. Leerink Swann initiated the shares of VCEL in report on Wednesday, April 4 with “Buy” rating. The firm has “Buy” rating given on Thursday, April 12 by BTIG Research. The firm earned “Buy” rating on Monday, March 5 by BTIG Research.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: Seekingalpha.com which released: “Vericel Q1 Results: Full Speed Ahead” on May 27, 2018, also Globenewswire.com with their article: “Vericel to Present at the Jefferies 2018 Global Healthcare Conference” published on May 25, 2018, Nasdaq.com published: “Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option …” on June 05, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: Globenewswire.com and their article: “Vericel Corporation Announces Proposed Public Offering of Common Stock” published on May 30, 2018 as well as Streetinsider.com‘s news article titled: “After-Hours Stock Movers 05/30: (TLYS) (KEYS) (VSI) Higher; (CRSP) (VCEL) (BOX) Lower (more…)” with publication date: May 30, 2018.

Vericel Corporation (NASDAQ:VCEL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: